NCT04169997View on ClinicalTrials.gov

A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

404

Participants

Timeline

Start Date

December 24, 2019

Primary Completion Date

March 16, 2023

Study Completion Date

June 30, 2026

Conditions
Ovarian Cancer
Interventions
DRUG

IMP4927

IMP4297 tablet.The starting dose from 100mg QD

DRUG

Placebos

Placebos tablet.The starting dose from 100mg QD

Trial Locations (2)

Unknown

Sun Yat-sen University Cancer Center, Guanzhou

Fudan University Shanghai Cancer Center, Shanghai

Sponsors
All Listed Sponsors
lead

Impact Therapeutics, Inc.

INDUSTRY

NCT04169997 - A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer | Biotech Hunter | Biotech Hunter